Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience - Seite 2
Efficacy of Ruxolitinib Cream Among Patients with Atopic Dermatitis Based on Previous Medication History: Pooled Results from Two Phase 3 Studies (Abstract #27482)
Efficacy of Ruxolitinib Cream in Patients with Atopic Dermatitis Who Demonstrated Partial Responses: Pooled Analysis from Two Randomized Phase 3 Studies (Abstract #24916)
Ruxolitinib Cream Rapidly Decreases Pruritus in Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #26884)
Effects of Ruxolitinib Cream on Work Productivity and Activity Impairment in Patients with Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #28200)
Effect of Ruxolitinib Cream on Sleep Disturbance and Sleep Impairment: Pooled Analysis from Two Randomized Phase 3 Studies (Abstract #26887)
Patient-Reported Outcomes of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #28194)
Vitiligo (Category: Pigmentary Disorders & Vitiligo)
Addition of Narrow-Band Ultraviolet Light B Phototherapy to Ruxolitinib Cream in Patients with Vitiligo (Abstract #27636)
Correlation of the Vitiligo Area Scoring Index with Patient – and Physician-Reported Measures of Clinical Improvement in a Randomized, Double-Blind Phase 2 Study (Abstract #25486)
All presentations will be available on demand starting April 23, 2021, at 8 a.m. CT (9 a.m. ET), and can be accessed until July 12, 2021. Full session details and listings all presentations are available on the AAD VMX program: https://eposters.aad.org/categories.
About Ruxolitinib Cream
Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.
About Incyte Dermatology
Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.